Results 101 to 110 of about 32,200 (252)

Frederic Lewy: how the two World Wars changed his life, work, and name

open access: yesArquivos de Neuro-Psiquiatria
In 1912, Friedrich Lewy described the inclusion bodies present in Parkinson disease and in Lewy body dementia. Throughout his life, Lewy fought in two wars – on opposite sides.
Patrick Emanuell Mesquita Sousa-Santos   +2 more
doaj   +1 more source

Heterogenous Neuropathology in a Pedigree with RAB39B‐Related Parkinson's Disease

open access: yesMovement Disorders, EarlyView.
Abstract Background In 2015, we reported a family with Parkinson's disease resulting from the RAB39B p.G192R (c.574G>A) variant. Since then, two affected brothers from the family have undergone autopsy. Objectives To characterize neuropathological findings, assess intracellular distribution of RAB39B protein, and examine the effect of p.G192R on α ...
Caitlin Latimer   +15 more
wiley   +1 more source

Progression of Motor and Cognitive Functions in Isolated REM Sleep Behavior Disorder: A 7‐Year Prospective Matched Cohort Study

open access: yesMovement Disorders, EarlyView.
Abstract Background Although clinical markers (eg, motor and cognitive impairment) in isolated rapid eye movement sleep behavior disorder (iRBD) are associated with faster phenoconversion, their longitudinal trajectory patterns (linear or nonlinear) remain unclear.
Li Zhou   +17 more
wiley   +1 more source

Effect of Andaliman (Zanthoxylum Acanthopodium DC) Extracts on The Histological Display of Lewy Body in The Brain of Rotenone Induced Wistar Rats

open access: yesInternational Journal of Islamic Education, Research and Multiculturalism
Dementia Lewy Body (DLB) is a form of dementia characterized by abnormal accumulation of α-synuclein protein in the brain, forming lewy bodies that damage the function of neurons and nervous system.
Lubna Afina   +4 more
doaj   +1 more source

Gray Matter Microstructure Measured Using Diffusion Imaging as a Biomarker of Severity in Lewy Body Diseases

open access: yesMovement Disorders, EarlyView.
Abstract Background Despite widespread cortical involvement in Lewy body diseases, conventional gray matter magnetic resonance imaging (MRI) shows limited sensitivity. Diffusion‐weighted MRI‐derived microstructural measures have shown utility in Alzheimer's disease, but their application across the Lewy body disease spectrum remains limited ...
Angeliki Zarkali   +9 more
wiley   +1 more source

Lack of Cerebrospinal Fluid α‐Synuclein Seeding in VPS35 D620N‐ and LRRK2 Y1699C‐Linked Parkinson's Disease

open access: yes
Movement Disorders, EarlyView.
Letizia Santinelli   +18 more
wiley   +1 more source

The GBA1 p.E427K (p.E388K) Variant Is a Risk Factor for Synucleinopathies: A Meta‐Analysis

open access: yesMovement Disorders, EarlyView.
Abstract Background Variants in GBA1 are important genetic risk factors for synucleinopathies, including Parkinson's disease (PD). Although several GBA1 variants are established risk or severity modifiers, the role of the p.E427K variant remains unclear.
Leah V. Chifamba   +30 more
wiley   +1 more source

Sick sinus syndrome and high‐degree atrioventricular block in dementia with Lewy bodies and other dementia subtypes: A study of ≈ 73,000 patients with dementia

open access: yesAlzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION Lewy body pathology is commonly found in cardiac nervous tissue, including the cardiac conduction system. This study aimed to investigate the occurrence of sick sinus syndrome (SSS) and high‐degree atrioventricular block in dementia with ...
Isak Heyman   +3 more
doaj   +1 more source

Rare‐Variant Burden across Lysosomal Genes Implicates Sialylation and Ganglioside Metabolism in Parkinson's Disease

open access: yesMovement Disorders, EarlyView.
Abstract Background Lysosomal dysfunction is central to Parkinson's disease (PD) pathogenesis, with GBA1 representing the strongest established genetic risk factor. Numerous other genes involved in lysosomal sphingolipid, glycosphingolipid, and ceramide metabolism have been proposed as contributors to PD, highlighting the need for genetic analyses ...
Konstantin Senkevich   +21 more
wiley   +1 more source

Plasma p‐tau217 Versus p‐tau181 in Parkinson's Disease: Differential Associations with Alzheimer's Disease‐Related Neurostructural Changes and Cognitive Function

open access: yesMovement Disorders, EarlyView.
Abstract Background Plasma phosphorylated‐tau at threonine‐217 (p‐tau217) and threonine‐181 (p‐tau181) are scalable, minimally invasive biomarkers of Alzheimer's disease (AD) pathology. In Parkinson's disease (PD), AD co‐pathology may contribute to its clinical heterogeneity.
Eleonora Fiorenzato   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy